Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery in Vitro

Pharmaceutical Research

Volumn 32, Issue 10, 2015, Pages 3293-3308

  Pereira, Sara ^a,c   Lee, Jin ^a   Rubio, Noelia ^a   Hassan, Hatem A F M ^a   Suffian, Izzat Bin Mohamed ^a   Wang, Julie T W ^a   Klippstein, Rebecca ^a   Ballesteros, Belén ^b   Al Jamal, Wafa T ^c   Al Jamal, Khuloud T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CATALAN INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY ICN2   (Spain)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

A549; cancer cells; gene silencing; multi walled carbon nanotubes; siRNA

Indexed keywords

DOXORUBICIN; LIPOSOME; MULTI WALLED NANOTUBE; POLO LIKE KINASE 1; SMALL INTERFERING RNA; AMMONIUM DERIVATIVE; ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CATION;

A549 CELL LINE; AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CYCLOADDITION; ELECTRON MICROSCOPY; ENZYMATIC DEGRADATION; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIPOSOMAL DELIVERY; MTT ASSAY; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RNA HYBRIDIZATION; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; MEDICINAL CHEMISTRY; PROCEDURES; TUMOR CELL LINE;

AMMONIUM COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATIONS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOTUBES, CARBON; RNA, SMALL INTERFERING;

EID: 84942297300     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1707-1     Document Type: Article

References (29)

1. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. Am Assoc Pharm Sci J. 2010;12(4):492-503.
2. DA Laufer SD, Sczakiel G, Restle T. Selected strategies for the delivery of siRNA in vitro and in vivo. In: Erdmann JB, Volker A, editors. RNA technologies. Berlin Heidelberg: Springer; 2010. p. 29-58.
3. Uddin SN. Cationic lipids used in non-viral gene delivery systems. Biotechnol Mol Biol Rev. 2007;2(3):58-67.
4. Nunes A, Amsharov N, Guo C, Van den Bossche J, Santhosh P, Karachalios TK, et al. Hybrid polymer-grafted multiwalled carbon nanotubes for in vitro gene delivery. Small. 2010;6(20):2281-91.
5. Popov VN. Carbon nanotubes: properties and application. Mater Sci Eng R Rep. 2004;43(3):61-102.
6. Zhang Y, Bai Y, Yan B. Functionalized carbon nanotubes for potential medicinal applications. Drug Discov Today. 2010;15(11-12):428-35.
7. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. J Fed Am Soc Exp Biol. 2005;19(3):311-30.
8. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33(29):7138-50.
9. Battigelli A, Wang JTW, Russier J, Da Ros T, Kostarelos K, Al-Jamal KT, et al. Ammonium and guanidinium dendron-carbon nanotubes by amidation and click chemistry and their use for siRNA delivery. Small. 2013;9(21):3610-9.
10. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6(4):321-30.
11. Guerreiro AS, Fattet S, Kulesza DW, Atamer A, Elsing AN, Shalaby T, et al. A sensitized RNA interference screen identifies a novel role for the PI3K p110gamma isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res. 2011;9(7):925-35.
12. Maire V, Nemati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 2013;73(2):813-23.
13. Nakouzi NA, Cotteret S, Commo F, Gaudin C, Rajpar S, Dessen P, et al. Targeting CDC25C, PLK1 and CHEK1 to overcome docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget. 2014;5(3):667-78.
14. Sakurai Y, Hatakeyama H, Akita H, Harashima H. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm. 2014;11(8):2713-9.
15. Georgakilas V, Kordatos K, Prato M, Guldi DM, Holzinger M, Hirsch A. Organic functionalization of carbon nanotubes. J Am Chem Soc. 2002;124(5):760-1.
16. Al-Jamal KT, Gherardini L, Bardi G, Nunes A, Guo C, Bussy C, et al. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci U S A. 2011;108(27):10952-7.
17. Al-Jamal KT, Toma FM, Yilmazer A, Ali-Boucetta H, Nunes A, Herrero MA, et al. Enhanced cellular internalization and gene silencing with a series of cationic dendron-multiwalled carbon nanotube:siRNA complexes. J Fed Am Soc Exp Biol. 2010;24(11):4354-65.
18. Ali-Boucetta H, Al-Jamal KT, Muller KH, Li S, Porter AE, Eddaoudi A, et al. Cellular uptake and cytotoxic impact of chemically functionalized and polymer-coated carbon nanotubes. Small. 2011;7(22):3230-8.
19. Ali-Boucetta H, Al-Jamal KT, Kostarelos K. Cytotoxic assessment of carbon nanotube interaction with cell cultures. Methods Mol Biol. 2011;726:299-312.
20. Samori C, Ali-Boucetta H, Sainz R, Guo C, Toma FM, Fabbro C, et al. Enhanced anticancer activity of multi-walled carbon nanotube-methotrexate conjugates using cleavable linkers. Chem Commun. 2010;46(9):1494-6.
21. Horiba S. Carbon nanotube applications: scientific H; 2014. Available from: http://www.horiba.com/scientific/products/particle-characterization/applications/carbon-nanotubes/.
22. Lacerda L, Ali-Boucetta H, Kraszewski S, Tarek M, Prato M, Ramseyer C, et al. How do functionalized carbon nanotubes land on, bind to and pierce through model and plasma membranes. Nanoscale. 2013;5(21):10242-50.
23. Xu XY, Xie K, Zhang XQ, Pridgen EM, Park GY, Cui DS, et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A. 2013;110(46):18638-43.
24. Saraswathy M, Gong SQ. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Mater Today. 2014;17(6):298-306.
25. Karchemski F, Zucker D, Barenholz Y, Regev O. Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells. J Control Release. 2012;160(2):339-45.
26. Miyako E, Kono K, Yuba E, Hosokawa C, Nagai H, Hagihara Y. Carbon nanotube-liposome supramolecular nanotrains for intelligent molecular-transport systems. Nat Commun. 2012;3:1226.
27. Yang RH, Jin JY, Chen Y, Shao N, Kang HZ, Xiao Z, et al. Carbon nanotube-quenched fluorescent oligonucleotides: probes that fluoresce upon hybridization. J Am Chem Soc. 2008;130(26):8351-8.
28. Degenhardt Y, Lampkin T. Targeting polo-like kinase in cancer therapy. Clin Cancer Res. 2010;16(2):384-9.
29. Ali-Boucetta H, Al-Jamal KT, McCarthy D, Prato M, Bianco A, Kostarelos K. Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chem Commun. 2008;4:459-61.